Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
  • Between 1990/1991 and 2008, the overall cancer mortality rates decreased by 22.9 percent in men and 15.3 percent in women—around 1,024,400 deaths avoided—primarily due to reductions in tobacco use among…  
  • FDA Cancer Approvals for Aug 2014 to July 2015